ReviewJournal of clinical microbiology2016
New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides.
Review in Journal of clinical microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Oxazolidinones in the Clinical Management of Staphylococcal Infection-Linezolid or Tedizolid? A review on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS).The Journal of antimicrobial chemotherapy · 2026Review
- Resistance to last-resort antibiotics in enterococci.FEMS microbiology reviews · 2025Review
- Use of oxazolidinones (linezolid or tedizolid) for the treatment of breast infections. A case series from a tertiary referral hospital.Infection · 2024Article
- Periprosthetic hip infection: Current concepts and the Wrightington experience.Journal of clinical orthopaedics and trauma · 2024Article
- Genetics Behind the Glycosylation Patterns in the Biosynthesis of Dalbaheptides.Frontiers in chemistry · 2022Review
- Article
- Characterization of a Lytic Bacteriophage vB_EfaS_PHB08 Harboring Endolysin Lys08 AgainstMicroorganisms · 2020Article
- New developments and future challenges in prevention, diagnosis, and treatment of prosthetic joint infection.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2020Review
- Radiosynthesis and Biodistribution ofACS infectious diseases · 2020Article
- Linezolid- and Vancomycin-resistant Enterococcus faecium in Solid Organ Transplant Recipients: Infection Control and Antimicrobial Stewardship Using Whole Genome Sequencing.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- Structural basis of translation inhibition by cadazolid, a novel quinoxolidinone antibiotic.Scientific reports · 2019Article
- New Innovations in the Treatment of PJI and Biofilms-Clinical and Preclinical Topics.Current reviews in musculoskeletal medicine · 2018Review
- Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus: Three major threats to hematopoietic stem cell transplant recipients.Transplant infectious disease : an official journal of the Transplantation Society · 2017Review
- Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections.Drug design, development and therapy · 2017Review
- Global Emergence and Dissemination of Enterococci as Nosocomial Pathogens: Attack of the Clones?Frontiers in microbiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growing problem of antimicrobial resistance among bacterial pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), has reached a critical state. Tedizolid phosphate, dalbavancin, and oritavancin have recently been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and represent the next generation of oxazolidinones and lipoglycopeptides. All three agents exhibit in vitro activity and clinical efficacy against MRSA. Tedizolid phosphate and oritavancin demonstrate in vitro activity against VRE. These new Gram-positive agents are reviewed here.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.